A phase I study of HYB2055 in patients (pts) with advanced solid malignancies

Autor:	Asim Amin, S. Park, Shakun Malik, Jimmy J. Hwang, S. Agrawal, T. M. Sullivan, John L. Marshall, M. J. Waxdal, T. E. Burns, R. R. Martin
Rok vydání:	2004
Předmět:	endocrine system Cancer Research Innate immune system Oligonucleotide business.industry TLR9 chemical and pharmacologic phenomena Human cell Phase i study Oncology Cancer research Medicine In patient business Receptor
Zdroj:	Journal of Clinical Oncology. 22:3111-3111
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.3111
Popis:	3111 Background: HYB2055 (IMOxine) is a 2nd generation immunomodulatory oligonucleotide (IMO TM) that is thought to activate the innate immune system through the TLR9 receptor. In human cell-based ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d0dd43ea2c997e989d4cb78aced7ca8e https://doi.org/10.1200/jco.2004.22.90140.3111 Zobrazit plný text záznamu